ES2247336T3 - Procedimiento de activacion de farmacos mediante una trituradora vibracional. - Google Patents

Procedimiento de activacion de farmacos mediante una trituradora vibracional.

Info

Publication number
ES2247336T3
ES2247336T3 ES02732748T ES02732748T ES2247336T3 ES 2247336 T3 ES2247336 T3 ES 2247336T3 ES 02732748 T ES02732748 T ES 02732748T ES 02732748 T ES02732748 T ES 02732748T ES 2247336 T3 ES2247336 T3 ES 2247336T3
Authority
ES
Spain
Prior art keywords
vibrational
crusher
pharmacy
drug
activation procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02732748T
Other languages
English (en)
Inventor
Luca Dobetti
Leonardo Rabaglia
Massimo Bresciani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals Holdings Ireland ULC
Original Assignee
Eurand Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Pharmaceuticals Ltd filed Critical Eurand Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2247336T3 publication Critical patent/ES2247336T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/14—Mills in which the charge to be ground is turned over by movements of the container other than by rotating, e.g. by swinging, vibrating, tilting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crushing And Grinding (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Procedimiento para activar un fármaco mediante la co-trituración del fármaco con un transportador farmacéutico, estando dicho procedimiento caracterizado por: - la co-trituración se realiza en una trituradora vibracional equipada con dispositivos para regular la frecuencia de vibración; - el grado de activación deseado se obtiene variando la frecuencia de vibración, mientras que se mantiene constante la amplitud de vibración.
ES02732748T 2001-06-29 2002-06-03 Procedimiento de activacion de farmacos mediante una trituradora vibracional. Expired - Lifetime ES2247336T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE20010620 2001-06-29

Publications (1)

Publication Number Publication Date
ES2247336T3 true ES2247336T3 (es) 2006-03-01

Family

ID=11042807

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02732748T Expired - Lifetime ES2247336T3 (es) 2001-06-29 2002-06-03 Procedimiento de activacion de farmacos mediante una trituradora vibracional.
ES02754775T Expired - Lifetime ES2231723T3 (es) 2001-06-29 2002-06-27 Procedimiento para activacion de farmacos en un molino vibracional.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02754775T Expired - Lifetime ES2231723T3 (es) 2001-06-29 2002-06-27 Procedimiento para activacion de farmacos en un molino vibracional.

Country Status (10)

Country Link
US (2) US20040166155A1 (es)
EP (1) EP1409140B1 (es)
JP (1) JP2004530557A (es)
AT (1) ATE301499T1 (es)
AU (1) AU2002304659B2 (es)
CA (1) CA2450900C (es)
DE (1) DE60205491T2 (es)
ES (2) ES2247336T3 (es)
NZ (1) NZ530825A (es)
WO (1) WO2003002258A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9918635B2 (en) 2008-12-23 2018-03-20 Roche Diabetes Care, Inc. Systems and methods for optimizing insulin dosage
US10437962B2 (en) 2008-12-23 2019-10-08 Roche Diabetes Care Inc Status reporting of a structured collection procedure
US20120011125A1 (en) 2008-12-23 2012-01-12 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
JP5694948B2 (ja) 2008-12-23 2015-04-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 慢性病患者の診断支援または治療支援のための構造化検査方法及びその装置
US9117015B2 (en) 2008-12-23 2015-08-25 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US10456036B2 (en) 2008-12-23 2019-10-29 Roche Diabetes Care, Inc. Structured tailoring
US8849458B2 (en) 2008-12-23 2014-09-30 Roche Diagnostics Operations, Inc. Collection device with selective display of test results, method and computer program product thereof
EP2438430A1 (en) * 2009-06-03 2012-04-11 The Trustees of Columbia University in the City of New York X-ray characterization of solid small molecule organic materials
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
WO2012063246A1 (en) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Amorphous form of lurasidone hydrochloride
US20120173151A1 (en) 2010-12-29 2012-07-05 Roche Diagnostics Operations, Inc. Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels
US8755938B2 (en) 2011-05-13 2014-06-17 Roche Diagnostics Operations, Inc. Systems and methods for handling unacceptable values in structured collection protocols
US8766803B2 (en) 2011-05-13 2014-07-01 Roche Diagnostics Operations, Inc. Dynamic data collection
US8981095B2 (en) 2011-07-28 2015-03-17 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3630774A (en) * 1968-08-14 1971-12-28 Corn Products Co Disrupted granular starch products and methods of making them
US3744726A (en) * 1971-04-28 1973-07-10 British Petroleum Co Metal flakes
US4076935A (en) * 1974-12-13 1978-02-28 Hoechst Aktiengesellschaft Grinding method for cellulose
DE2742575C2 (de) * 1977-09-22 1982-05-19 Hoechst Ag, 6000 Frankfurt Verfahren zur Feinverteilung von Pigmenten der Dioxazinreihe
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
KR100277320B1 (ko) * 1992-06-03 2001-01-15 가나이 쓰도무 온라인 롤 연삭 장치를 구비한 압연기와 압연 방법 및 회전 숫돌
DE4343742C2 (de) * 1993-12-21 1999-10-14 Krupp Polysius Ag Scheibenschwingmühle
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
JPH11503749A (ja) * 1995-04-20 1999-03-30 ベクトルファーマ インターナショナル エス．ピー．エイ． 支持剤であるデンプングリコール酸ナトリウムとの複合物およびその製品

Also Published As

Publication number Publication date
DE60205491T2 (de) 2006-06-01
ATE301499T1 (de) 2005-08-15
CA2450900A1 (en) 2003-01-09
EP1409140A1 (en) 2004-04-21
US20040166155A1 (en) 2004-08-26
EP1409140B1 (en) 2005-08-10
JP2004530557A (ja) 2004-10-07
US20080251615A1 (en) 2008-10-16
ES2231723T3 (es) 2005-05-16
AU2002304659B2 (en) 2006-11-16
CA2450900C (en) 2010-08-24
WO2003002258A1 (en) 2003-01-09
US7793871B2 (en) 2010-09-14
NZ530825A (en) 2005-03-24
DE60205491D1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
ES2247336T3 (es) Procedimiento de activacion de farmacos mediante una trituradora vibracional.
WO2002076402A3 (en) Fatty amine drug conjugates
PT1180062E (pt) Metodo para a producao de micro e nanoparticulas morfologicamente uniformes utilizando micromisturadores
AU2002305099A1 (en) Fatty alcohol drug conjugates
EP1507556A4 (en) CALICHEAMICINE DERIVATIVE VECTOR-TYPE CONJUGATES
DK1148891T3 (da) Fremgangsmåde til emballering af et oxidationsfölsomt medicinsk stof
BR0010262A (pt) Composição para formar um aerossol, processo de preparação e de aerossolização de uma composição, e, dispositivo gerador de aerossol
AR032132A1 (es) Composicion farmaceutica que comprende una combinacion de un compuesto de tramadol y una droga anticonvulsiva y uso de la combinacion para preparar un medicamento
MX2011001384A (es) Composiciones y metodos para tratar trastornos psiquiatricos.
DE69812159D1 (de) Derivate des adamantan
PL371736A1 (en) Method for administering glp-1 molecules
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
CY1112946T1 (el) 4-υδροξυβενζομορφανια
ATE313532T1 (de) Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
CY1107714T1 (el) Φαρμακευτικες συνθεσεις μοδαφινιλιου
TW200510002A (en) Solid pharmaceutical preparation
WO2002067967A3 (en) Method of treating rhinitis or sinusitis
HUP0300290A2 (hu) Érkárosító hatású kombinácíós készítmény és terápia
MY137620A (en) Therapeutic treatment
BRPI0607351A2 (pt) métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20
ATE411981T1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ES2159034T3 (es) Trituradora vibratoria de cono.
EP1834646A4 (en) ULTRASONIC CANCER THERAPY ACCELERATOR AND CYTOTOXIC AGENT
ATE194909T1 (de) Zusammensetzung mit natriumstärkeglycolat als grundlagenmaterial und daraus hergestellte produkte
PA8552301A1 (es) Metodo para el tratamiento de insomnio primario